Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.66 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11885632 | 1.00 | GPR119 (0.66) | GPR119USP30F2RL3 | |
| SCHEMBL13596325 | 0.91 | GPR119 (0.59) | GPR119 | |
| SCHEMBL1118035 | 0.90 | GPR119 (0.78) | GPR119F2RL3 | |
| SCHEMBL14874940 | 0.89 | GPR119 (0.57) | GPR119 | |
| SCHEMBL3489223 | 0.88 | GPR119 (0.80) | GPR119 | |
| SCHEMBL11885631 | 0.88 | GPR119 (0.80) | GPR119 | |
| SCHEMBL1118239 | 0.81 | GPR119 (0.79) | GPR119F2RL3 | |
| SCHEMBL14874841 | 0.81 | GPR119 (0.62) | GPR119 | |
| SCHEMBL8024812 | 0.81 | GPR119 (0.54) | GPR119 | |
| SCHEMBL1118394 | 0.81 | GPR119 (0.54) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111107-B1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC (US) | 2013-04-24 | — | — | EP | claimed |
| US-8227495-B2 | 2,4-disubsituted thiazoles and pharmaceutical compositions thereof | METABOLEX INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | CYMABAY THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS INC (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2018026890-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2018-01-25 | — | — | US | disclosed |
| US-9737537-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170105993-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2017-04-20 | — | — | US | disclosed |
| US-20150239881-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2280704-B1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20130281691-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS, INC. | 2013-10-24 | — | — | US | disclosed |
| EP-2111107-B1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8288384-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8227495-B2 | 2,4-disubsituted thiazoles and pharmaceutical compositions thereof | METABOLEX INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100130511-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100087465-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2010-04-08 | — | — | US | disclosed |
| US-7638541-B2 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087465-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885USP30 3621/4885F2RL3 585/4885 |
| US-20130281691-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885USP30 3621/4885F2RL3 585/4885 |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | GPR119, GIPR, GLP1R | GPR119 1/4885USP30 3857/4885F2RL3 375/4885 |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | GPR119, GLP1R, DPP4 | GPR119 1/4885USP30 2791/4885F2RL3 536/4885 |
| US-20150239881-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885USP30 3621/4885F2RL3 585/4885 |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | GPR119, GIPR, GLP1R | GPR119 1/4885USP30 3857/4885F2RL3 375/4885 |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885USP30 3621/4885F2RL3 585/4885 |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | SLC5A2, IAPP, GPR119 | GPR119 3/4885USP30 2070/4885F2RL3 3002/4885 |
| US-20170105993-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885USP30 3621/4885F2RL3 585/4885 |
| US-20100130511-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885USP30 3621/4885F2RL3 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.